Patents by Inventor Robert A. Volkmann

Robert A. Volkmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20210403474
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: February 12, 2021
    Publication date: December 30, 2021
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES
    Publication number: 20210299137
    Abstract: Compounds for treatment of diseases having acidic or hypoxic diseased tissues and pharmaceutical compositions comprising the compounds, as well as methods for making and using the compounds and compositions.
    Type: Application
    Filed: October 28, 2020
    Publication date: September 30, 2021
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Dalton King, Robert A. Volkmann, Yana Reshetnyak, Oleg Andreev, Don Engleman
  • Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B
    Patent number: 11116749
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 14, 2021
    Assignee: CADENT THERAPEUTICS, INC
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20210107916
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Application
    Filed: January 31, 2020
    Publication date: April 15, 2021
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Thienopyrimidinone NMDA receptor modulators and uses thereof
    Patent number: 10973825
    Abstract: Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 13, 2021
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
    Patent number: 10933069
    Abstract: Compounds for treatment of diseases having acidic or hypoxic diseased tissues and pharmaceutical compositions comprising the compounds, as well as methods for making and using the compounds and compositions.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: March 2, 2021
    Assignee: Cybrexa 1, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Dalton King, Robert A. Volkmann, Yana Reshetnyak, Oleg Andreev, Don Engleman
  • PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS
    Publication number: 20210009536
    Abstract: The present invention relates to peptide conjugates of microtubule-targeting agents such as maytansinoid derivatives which are useful for the treatment of diseases such as cancer.
    Type: Application
    Filed: July 9, 2020
    Publication date: January 14, 2021
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS
    Publication number: 20210009719
    Abstract: The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.
    Type: Application
    Filed: July 9, 2020
    Publication date: January 14, 2021
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B
    Publication number: 20200369610
    Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Applicant: CADENT THERAPEUTICS, INC.
    Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITI
  • OXABICYCLOHEPTANE PRODRUGS
    Publication number: 20200325151
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: February 5, 2020
    Publication date: October 15, 2020
    Inventors: John S. KOVACH, Robert VOLKMANN, Anthony MARFAT
  • N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B
    Patent number: 10781174
    Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: September 22, 2020
    Assignee: CADENT THERAPEUTICS, INC.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 10752633
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: August 25, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20200131190
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 30, 2020
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 10626122
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 21, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Oxabicycloheptane prodrugs
    Patent number: 10618908
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: April 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20200087323
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Application
    Filed: December 22, 2017
    Publication date: March 19, 2020
    Inventors: David R. Anderson, Robert A. Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 10584131
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: March 10, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20200039987
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Thienopyrimidinone NMDA receptor modulators and uses thereof
    Patent number: 10500205
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: December 10, 2019
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • OXABICYCLOHEPTANE PRODRUGS
    Publication number: 20190359627
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: June 12, 2019
    Publication date: November 28, 2019
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat